The guidance focuses on GLP-1 therapies – medicines such as liraglutide, semaglutide and tirzepatide – and offers conditional recommendations on how they can be used safely as part of long-term treatment. Living with obesity More than one billion people worldwide live with obesity, which was linked to 3.7 million deaths...
